Latest Androgen Stories
Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.
In its early stages, prostate cancer requires androgens (hormones that promote the development and maintenance of male sex characteristics) for growth, and current first-line therapies target the receptor for these hormones to slow cancer's development and spread.
Implications for treatment of polycystic ovarian syndrome, No 1 cause of female infertility
Drugs should be developed to target gene fusions in prostate cancer, research shows.
Van Andel Research Institute (VARI) scientists have determined how two proteins required for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved treatments for the disease.
IAD shows tolerability and quality of life advantages.
On rare occasions, an infant is born with outward appearance of a female but the XY chromosomes of a male.
New research in the FASEB Journal suggests that manipulating testicular hormone levels can turn male fertility on and off, representing new strategy for developing 'the pill' for men and for treating male infertility.
Researchers from Boston University School of Medicine (BUSM) in collaboration with researchers from Lahey Clinic Northshore, Peabody, Mass., believe that androgen deficiency might be the underlying cause for a variety of common clinical conditions, including diabetes, erectile dysfunction, metabolic syndrome and cardiovascular disease (CVD). These findings appear in the September/October issue of the Journal of Andrology.
A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.
- A political dynamiter.